Bispecific antibody and ADC together impress in early study ...

Early efficacy among the highest seen in lung cancer, expert says ...

BlossomHill Therapeutics (BLSM) said Tuesday that updated data from the phase 1/2 SOLARA trial of BH-30643 showed a 45% objective response rate and an 88% disease control rate in patients with EGFR ...

Atezolizumab showed modest response rates in NSCLC patients previously treated with PD-1 inhibitors, with a suggested baseline response rate of 10% for new ICI combinations. The study's primary ...

Pyxis Oncology (PYXS) reported a 36% confirmed response rate and 94% disease control rate in updated phase 1 data for micvotabart pelidotin in second-line and beyond recurrent/metastatic head and neck ...

Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma patients. Cytokine release syndrome occurred in 70% of patients, with lower ...

Please provide your email address to receive an email when new articles are posted on . Dostarlimab conferred clinical complete responses in all patients treated during a phase 2 trial.. Circulating ...

Role of induction chemotherapy in locally advanced oropharyngeal carcinoma in Indian population. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...

Please provide your email address to receive an email when new articles are posted on . Furthermore, a study Kerschbaumer had previously co-authored found that placebo-treated patients on background ...

Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma. This is an ASCO Meeting ...

BARCELONA — Restarting an anti-CGRP monoclonal antibody (mAb) for migraine prevention after a gap in treatment often leads to a lower efficacy rate in the second treatment period, a new study suggests ...

SAN JUAN, Puerto Rico -- Two inhibitors of the same immune checkpoint family produced high response rates and evidence of durability in preliminary studies of advanced gynecologic cancers. Patients ...